EUVIMEDEUVIMED entdecken
Crossref

Lynch Syndrome in the General Population: Clinical Phenotype of PMS2 Pathogenic Variants

Kelly M. Schiabor Barrett, Catherine Hajek, James Lu, Kate Lynch, Leigha Senter, Amy C. Sturm, Chad R. Haldeman-Englert, Douglas Stoller, Christopher N. Chapman, C. Anwar A. Chahal, Daniel P. Judge, Douglas A. Olson und 4 weitere

JCO Oncology Advances · 2026-04 · 3 (2)

DOI: 10.1200/oa-25-00075 ↗

Kurz gefasst

Fachartikel in der Zeitschrift JCO Oncology Advances, 2026-04. Verfasst von Kelly M. Schiabor Barrett und 15 weiteren Autor:innen. Die Arbeit nennt 24 Literaturangaben.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE The Lynch syndrome (LS) genes, MLH1 , MSH2 , MSH6 , and PMS2 , are considered to be some of the highest-priority genes to be tested for population genomic screening, with the aim to prevent and detect cancers early in those with a higher risk for such diagnoses. The objective of this study was to determine the risk of cancer associated with pathogenic variants in MLH1 , MSH2 , MSH6 , or PMS2 in the general population to build evidence-based guidelines for population genomic screening METHODS This retrospective case-control study uses Helix Research Network data from 230,159 participants across nine US health systems. Variant interpretation was performed following the American College of Medical Genetics and Association for Molecular Pathology guidelines. Clinical diagnoses were identified from electronic health records and claims data for 11 cancer types associated with LS, including colorectal and endometrial cancers. RESULTS Individuals with pathogenic variants in MLH1 , MSH2 , and MSH6 showed substantial risk for LS-related cancers compared with those without pathogenic variants. Conversely, individuals with pathogenic variants in PMS2 had no increase in risk for all 11 LS-associated cancers with hazard ratio (HR) of 1.0 (95% CI, 0.6 to 1.8) compared with those without a pathogenic variant. There was a small increase in risk when restricting the analysis to colorectal cancer with an HR of 3.5 (1.7-7.4). This increase in colorectal cancer risk was predominantly observed after age 60 years, 10 years after US Preventive Services Task Force guidelines recommend starting colonoscopies for the average population. Up to age 60 years, 2.6% of individuals with PMS2 pathogenic variants were diagnosed with colorectal cancer, closer to the general population (0.7%) than those with MLH1 (37.3%), MSH2 (28.9%), or MSH6 (6.7%) pathogenic variants. For 100,000 individuals screened for PMS2 , 854 additional colonoscopies would be performed, which would prevent or detect early 3.2 colorectal cancers. CONCLUSION This analysis across nine health systems highlights the clinical phenotypes of PMS2 pathogenic germline variants in the entire population.

Zitieren

APA

Barrett, K. M. S., Hajek, C., Lu, J., Lynch, K., Senter, L., Sturm, A. C., Haldeman-Englert, C. R., Stoller, D., Chapman, C. N., Chahal, C. A. A., Judge, D. P., Olson, D. A., Grzymski, J. J., Lee, W., Cirulli, E. T., & Bolze, A. (2026). Lynch Syndrome in the General Population: Clinical Phenotype of PMS2 Pathogenic Variants. JCO Oncology Advances, 3(2). https://doi.org/10.1200/oa-25-00075

Vancouver

Barrett KMS, Hajek C, Lu J, Lynch K, Senter L, Sturm AC, et al. Lynch Syndrome in the General Population: Clinical Phenotype of PMS2 Pathogenic Variants. JCO Oncology Advances. 2026;3(2). doi:10.1200/oa-25-00075

BibTeX
@article{Barrett2026,
  author = {Barrett, Kelly M. Schiabor and Hajek, Catherine and Lu, James and Lynch, Kate and Senter, Leigha and Sturm, Amy C. and Haldeman-Englert, Chad R. and Stoller, Douglas and Chapman, Christopher N. and Chahal, C. Anwar A. and Judge, Daniel P. and Olson, Douglas A. and Grzymski, Joseph J. and Lee, William and Cirulli, Elizabeth T. and Bolze, Alexandre},
  title = {Lynch Syndrome in the General Population: Clinical Phenotype of PMS2 Pathogenic Variants},
  journal = {JCO Oncology Advances},
  year = {2026},
  volume = {3},
  number = {2},
  doi = {10.1200/oa-25-00075}
}
Kostenlos starten →